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Poor medication adherence among persons diagnosed 
with a severe and persistent mental illness causes 
repeated psychotic episodes that lead to 
rehospitalization, incarceration, adverse side effects, 
and suicide. This research study is exploratory in nature 
and utilized a methodology that elucidates the reasons 
for psychotropic nonadherence from the client's 
perspective. This study included 16 participants 
diagnosed with a severe and persistent mental illness, 
who are currently receiving case management and 
psychiatric services from a community-based mental health 
agency. The survey instrument is a 10-item, one-to-one, 
semi-structured interview. Open-ended questions were 
designed to generate possible barriers to psychotropic 
adherence. At the conclusion of this study, researchers 
identified themes from the participants' responses. Many 
of the same themes stated in current research were 
identified in the responses (i.e., side effects, 
relationship with mental health professionals, and 
insight) . The response's derived from this study can be 
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This chapter provides an overview of the problems 
persons diagnosed with a severe and persistent mental 
illness experience as a result of nonadherence to 
psychotropic medication, the importance of studying 
nonadherence, the role of the mental health social 
worker, the methodology employed for this study, and its 
potential contributions to the field of social work.
Problem Statement
According to a study by the World Health
Organization "mental illness (including depression, 
bipolar disorder, and schizophrenia) is the leading cause 
of disability worldwide, accounting for 25 percent of all 
disabilities across major industrialized countries" (New 
Freedom Commission on Mental Health, SMA-03-3832, 2003). 
Unfortunately, most people do not seek mental health 
treatment, which can lead to debilitating symptoms and 
diminished quality of life (Bond, Drake, Mueser, & 
Latimer, 2001). Medication nonadherence in individuals 
with a severe and persistent mental illness (SPMI) is 
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highly correlated with increased levels of symptomatology 
leading to relapse, adverse side effects, 
rehospitalization, incarceration, and suicide (Balon, 
2002; Hewitt & Birchwood, 2002; Kopelowicz & Lieberman, 
2003; Pinikahana, Happell, Taylor, & Keks, 2002; Trauer & 
Sacks, 1998; Wykes & Gournay, 2002).
In the U.S. alone, 22-23 percent of the adult 
population, 44 million people has a mental illness, of 
which, 2.6 percent-has a SPMI (U.S. Department of Health 
and Human Services [USDHHS], 1999). Furthermore, studies 
indicate that more than 50 percent of individuals taking 
psychotropics are nonadherent and at risk of relapse 
(Byrne, Deane, Lambert & Coombs, 2004; Dixon, Weiden, 
Torres & Lehman, 1997; Dodler, Lacro, Dunn & Jeste, 2002; 
Hogarty & Ulrich, 1998; Hughes & Hill, 1997).
Wykes and Gournay (2002) suggest that persons with a 
SPMI considered to be medication nonadherent have not 
taken their medication regimen as prescribed by a mental 
health professional. Although several attempts have been 
made to measure medication adherence through blood/urine 
tests, psychiatric assessments, pill counts, and 
self-reports, none of their methods were effective (Wykes 
& Gournay, 2002).
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A study by Trauer and Sacks (1998) compared 
judgments concerning the medication adherence between the 
individual with the SPMI, the case manager, and the 
doctors, and found that "12.5 percent, or one in eight, 
of the clients thought by both clinicians to be 
compliant, rated themselves as noncompliant."
According to Hayward and Chan (1995), "...adherence 
to these drug regimes offers hope for a greatly increased 
quality of life for the long term mentally ill as well as 
an enormous saving of public money." Despite the hope 
pharmacotherapy brings to individuals with SPMI in the 
recovery process, many individuals continue to be 
nonadherent.
Under the rights-driven model, one of two approaches 
to treatment refusal, clients have the right to refuse 
medication regardless of the benefit (Kasper, Hoge, 
Feucht-Haviar, Cortina, & Cohen, 1997).
Micro/Macro Policy.
The National Association of Social Workers (NASW) 
Code of Ethics (1999) delineates ethical principles which 
guide both micro and macro practitioners. The ethical 
principle of social justice calls for social workers to 
pursue social change through advocacy and political 
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activism. Recently, social workers and mental health 
clients marched on California's state capital advocating 
for increased mental health funding. Their advocacy was 
successful as California voters passed Proposition 63, 
the Mental Health Services Act, which will generate an 
estimated $650 million during the first fiscal year, 
2005-2006 (California Department of Mental Health, 2005).
Currently, micro and macro level social workers are 
working on planning teams with other mental health 
professions creating a three-year plan for Proposition 63 
funding expenditures. Once funding is awarded, macro 
practice social workers will collaborate on 
multidisciplinary teams, designing new mental health 
programs, and expanding existing programs to address such 
issues as treatment nonadherence with populations like 
those with SPMI. Without the advocacy of macro and micro 
practice social workers, community-based agencies will 
continue to be under staffed and under funded, making it 
difficult to initiate effective evidenced-based treatment 
that address nonadherence.
Social Work Roles
Mental health social workers play a multi-faceted 
role in the client/professional relationship, including 
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advocacy for reduced physical and psychological side 
effects of psychotropics, remaining client focused by 
bridging the gap between parallel treatment modalities, 
working on an inter-disciplinary teams applying a 
holistic treatment perspective, and educating clients 
about their medication regimen (Bentley & Walsh, 2001, 
p. 43). Social workers, committed to these roles, 
ethically fulfill their duties and responsibilities as 
change agents within the community.
Purpose of the Study
The purpose of this qualitative study was to 
identify barriers to psychotropic adherence regimens in 
clients with SPMI. Medication nonadherence perpetuates 
the cycle of psychotic episodes, which leads to 
rehospitalization, incarceration, and homeless nights. 
This series of events has been coined "the revolving door 
phenomenon" (Hewitt & Birchwood, 2002; Kopelowicz & 
Lieberman, 2003). Until mental health professionals 
listen to the population they serve and better understand 
the reasons for psychotropic nonadherence, treatment 
interventions will continue to be noneffective.
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This study was conducted at the Mental Health 
Association of Orange County (MHAOC), a community-based 
nonprofit agency. This study is in keeping with the 
intent of the AB2034 Program, authorized in 1999, by the 
California State Legislature, to provide intensive 
recovery services to individuals diagnosed with a SPMI 
such as schizophrenia, schizoaffective disorder, bipolar 
disorder, and major depressive disorder, .secondary 
diagnoses of substance disorders., and homelessness or 
being at risk of becoming homeless. These individuals are 
referred to the AB2034 program through Orange County 
Department of Behavioral Health, Homeless Outreach 
Program.
The AB2034 program serves adults over 18 years of 
age, both male and female, representing diverse cultural 
and religious backgrounds. With respect to individuals' 
cultural beliefs, practices, and personal goals, case 
managers link clients to practical services that promote 
recovery and social integration. These services include 
counseling, pharmacotherapy, housing, financial support 
through SSI, medical and dental benefits, food and 
clothing, detoxification, rehabilitation programs, and 
social skills training.
6.
Studies identify numerous reasons for psychotropic 
nonadherence such as adverse side-effects (i.e. excessive 
weight gain, sexual dysfunction), client/clinician 
relationship, lack of insight, and complexity of 
medication regimen (Azrin & Teichner, 1998; Balon, 2002; 
Dixon et al., 1997; Edlund, Wang, Berglund, Katz, Lin & 
Kessler, 2002; Hewitt & Birchwood, 2002; Kane & Nemec, 
2002; Love, 2002; Nasrallah & Korn, 2002; Rosenberg, 
Bleiberg, Koscis & Gross, 2003). Recent studies of 
psychotropic nonadherence indicate a significant 
correlation with the client/clinician relationship 
(Balon, 2002; Donnell, Lustig & Strauser, 2004; Gabbard & 
Kay, 2001; Kane & Nemec, 2002; Noordsy et al., 2002; 
Trauer & Sacks, 1998). Creating a positive, mutual 
working relationship is vital to adherence practices of 
those with SPMIZ which essentially promotes recovery. 
Offering clients, especially those hard to reach, the 
opportunity to enhance their standard of living, guides 
this studies methodological rational.
Research Design
This research study is exploratory in nature and 
used a qualitative research methodology to elucidate the 
reasons for psychotropic nonadherence, from the SPMI 
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individual's perspective. The instrument used in this 
study was specifically designed to draw out participants' 
responses to psychotropic adherence questions based on 
their own experiences and perceptions. Due to limited 
research in this area no standardized measure was 
available. Data was collected through a semi-structured 
interview and recorded verbatim. Using a table of random 
numbers, researcher selected a random point on the table, 
reading across the rows, or down the columns, writing a 
list of the first 20 numbers found. These 20 numbers were 
used to identify the sample of this study.
A Licensed Family and Marriage Therapist 
administered the Mini Mental Status Exam (MMSE) to 
prospective participants to asses their current mental 
status. A minimum score of 21 was used to screen 
prospective participants into this study. After 
participating in the semi-structured qualitative 
interview, participants received an envelope containing 
$15 cash in return for their time and effort.
Significance of the Project for Social Work
This study is important to social work practice 
because it validates the principles of empowerment by 
8
seeking a deeper understanding of the client's reasons 
for psychotropic nonadherence. Using a client-centered 
approach, researchers will engage clients with SPMI 
through personal interviews. Engagement is a powerful 
element of the working alliance supporting the ethical 
principles of social work practice. Furthermore, engaging 
clients and offering them the opportunity to discuss 
psychotropic regimen concerns, enhances the individual's 
inherent feelings of worth and self-determination.
Findings from this client-centered study provide a unique 
insight into adherence issues that will inform both the 
design and implementation of new treatment approaches.
Furthermore, approaching nonadherence issues from 
the client's perspective helps mental health 
professionals move from the biological confines of the 
medical model that often perpetuates victimization to a 
more hopeful model of recovery that promotes quality of 
life (Ragins, 1994). Strategies which attempt to improve 
adherence through increased dosage, change in medication, 
or modifying the formulation (oral to depot) are 
typically unsuccessful (Ragins, 1994).
Effective community-based.mental health agencies 
serving those with a SPMI use a dual-modality therapy 
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approach. Dual-modality is a combination of psychosocial 
rehabilitation (including psychotherapy) and 
pharmacological treatment. Crate (2003) notes that 
psychosocial rehabilitation is based on a number of 
psychological theories including: client-centered, 
rational emotive, and reality theory. Each of these 
theories promotes the ideal of client self-determination 
through conscious decision-making, an essential component 
of recovery.
Pharmacological treatment was ushered in the 1960's, 
and played a central role in the early stages of 
deinstitutionalization (Heyscue, Levin & Merrick, 1998). 
Psychotropic medication is the single leading treatment 
modality in mental health care nation wide, offering 
quicker relief from psychotic symptoms than psychosocial 
rehabilitation. Both treatment modalities have a place in 
the field of mental health, however, combining these 
treatment modalities (i.e., psychosocial rehabilitation 
and pharmacotherapy) produces the best results.
Several studies of psychotropic nonadherence have 
called for further investigation of treatment adherence. 
With over one-half of persons' with a SPMI nonadherent to 
psychotropic regimens, mental health social workers
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continue to seek answers■to address this crisis. The 
evaluation phase of this study is essential to the 
identification and implementation of effective 





This chapter will describe severe and persistent 
mental illness, determine costs involved in serving 
individuals with such illnesses, and the barriers to 
psychotropic adherence. It will also describe the 
different treatment modalities that are utilized with 
this population. For example, psychosocial therapy based 
interventions will be discussed in terms of improving 
medication adherence and insight into illness, and 
interventions based solely on pharmacotherapy. 
Dual-modality interventions that include psychosocial 
therapy and medication to assist severe and persistent 
mentally ill (SPMI) clients are also discussed. Finally, 
a discussion of the theories guiding this research 
project will conclude this chapter.
Severe and Persistent Mental Illness
Severe and persistent mental illness (SPMI) is 
determined by Federal regulations and "applies to mental 
disorders that interfere with some area of social 
functioning" (USDHHS, 1999) . The areas of social 
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functioning include problems with primary support group, 
social environment, education, occupation, housing, 
economic stability, access to health care services, legal 
system/crime, and other psychosocial and environmental 
areas (DSM-IV TR, American Psychiatric Association, 
2000).
Two components that warrant attention when 
addressing SPMI are the human and financial components. 
The human components are the problems that individuals 
with SPMI encounter, which include profound functional 
impairment in one or more of the above mention areas, and 
leads to loss of functioning in many different areas of 
life. The Advisory Mental Health Council estimated that 
nine percent of U.S. adults have mental disorders as well 
as deficits in functional abilities (as cited in USDHHS, 
1999).
The financial component involves the direct and 
indirect costs involved in serving SPMI clients. The 
category of direct costs includes "mental health 
institutions, sheltered homes, drugs, support costs, and 
social welfare" (Lindstrom & Bingefors, 2000, p. 114). 
The indirect costs are computed as loss of productivity 
in the workplace, school, and home due to premature death 
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or disability (USDHHS, 1999) . In 1996, the direct costs 
of mental health services totaled 69 billion dollars 
(USDHHS, 1999) . Additional indirect costs were calculated 
in 1990 to exceed 78 billion dollars (USDHHS, 1999). In 
addition to these direct and indirect costs to humanity, 
overall reduction in the quality of life for the clients 
should also be included (Lindstrom & Bingefors, 2000).
Barriers to Psychotropic Adherence
Many different barriers to medication adherence have 
been discussed in the literature. Barriers to medication 
adherence include, but are not limited to the following: 
medication regime confusion, lack of insight (into mental 
illness), denial of diagnosis, cultural belief systems, 
self-medication with illicit drugs and alcohol, side 
effects, and relationship between client and clinician. 
Side effects and relationship between client and 
clinician appear to be the two most important factors in 
treatment adherence. In fact, Seedat, Stein, and Wilson 
(2002) examined the drop out rates of clients engaged in 
treatment (pharmacotherapy and psychotherapy), noting 




Programs operating under the psychosocial model 
assist clients with psychotropic regime confusion, lack 
of insight, and denial of diagnosis. Lack of education 
was associated with medication nonadherence, discovering 
that clients were poorly informed of their diagnosis and 
treatment. Nearly one-half of those respondents 
discontinued medications due to side effects (Seedat et 
al., 2002). Louis-Simonet et al. (2004), on the other 
hand, utilized residents to perform a structured 
patient-centered discharge interview, concluding that 
patients exited the program with significantly increased 
knowledge about their medications. This study did not 
yield statistically significant results, most likely 
based on the lack of social support once clients were 
released from the hospital (Louis-Simonet et al., 2004).
Increased knowledge of medications in combination 
with social support has been shown to increase medication 
adherence (Ho et al., 1999). Hellwell (2002) also noted a 
link between insight into illness and medication 
adherence; in fact one out of five clients diagnosed with 
schizophrenia missed one week of medication during the 
first three months after hospitalization. Jordan,
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Tunnicliffe, and Sykes (2002) developed the SPMI clients' 
insight into illness and side effects of medication 
regimes by utilizing a checklist to assist clients to 
determine medication side effects. This checklist allowed 
clients to report unfavorable side effects in a timely 
manner to the psychiatrists once they understood that 
side effects were possible (Jordan et al., 2002).
Stawar and Allred (1999) discovered that the 
perceptions of the staff members and the clients differed 
considerably when concentrating on discontinuation of 
medication. They noted that very few staff members 
perceived confusion as a reason for medication 
nonadherence, whereas more than one-third of the 
residents did perceive it as such (Stawar & Allred, 
1999).
Cultural Barriers
Cultural barriers can further complicate 
psychotropic adherence in many different populations. 
Minorities encounter many barriers to receiving mental 
health services. "Mistrust and fear of treatment; 
different cultural ideas about illnesses and health; 
differences in help-seeking behaviors, language, and 
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communication; racism; varying rates of being uninsured; 
and discrimination by individuals and institutions" are 
many of the cultural barriers faced by minorities in 
receiving mental health services (New Freedom Commission 
on Mental Health, SMA-03-3832, 2003). Stotland (2003) 
noted that unspoken fears, such as the barriers listed 
above, affect the treatment regime. These fears can 
manifest in cultural beliefs that prevent a client from 
receiving greatly needed services.
For example, Asian culture views the mind and body 
as "unitary" compared to the European ideal of 
"dualistic". This belief tends to manifest in Asian 
patients as physical indicators, versus emotional 
symptoms (Lin & Cheung, 1999) , as mental illness is 
viewed as shameful. This can be a barrier, as Asian 
clients might not seek mental health services, due to the 
belief that the problem is physical.
The National Institute on Mental Health (USDHHS, 
1999) notes that the U.S. mental health system-is not 
equipped to meet'the needs of ethnic and racial minority 
populations. Cultural barriers (i.e., cultural beliefs) 
deter ethnic minorities from seeking treatment, and if 
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individuals seek treatment, their treatment plans may be 
inappropriate in nature (USDHHS, 1999).
Self-medicating Behaviors
Self-medicating (i.e., utilization of illicit drugs 
and/or alcohol) to reduce symptoms of SPMI clients is a 
direct barrier to medication adherence. Johnson, Brems, & 
Burke (2002) examined 104 clients in a substance abuse 
program, identifying 45 percent with an additional mental 
illness, indicating that many times the two problems 
cannot be separated. Ho et al. (1999) adds that treating 
dually diagnosed individuals is increasingly difficult as 
clients face "increased morbidity from substance induced 
psychotic exacerbation, dysphoria, anxiety, insomnia, and 
agitation" (p. 1765).
Side Effects
Studies with SPMI clients have demonstrated side 
effects in drug treatment plans as a major cause of 
medication discontinuation. Side effects range from 
weight gain to sexual dysfunction. Green, Patel, Goisman, 
Allison, and Blackburn (2000) state that psychotropic 
drugs used to treat schizophrenia have been linked to 
substantial weight gain. Green et al., (2000) examined 
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obesity in schizophrenic clients, noting that these same 
clients are at risk for. additional physical ailments such 
as Type II diabetes. Sexual side effects (i.e., sexual 
dysfunction, lack of desire, etc.) were reported by 62.5 
percent of males and 38.5 percent of females in a study 
conducted by Rosenberg et al. (2003). Of particular 
interest is that 50 percent of the clients "never or 
infrequently" voiced these concerns to their clinicians 
(Rosenberg et al., 2003). These findings suggest that the 
relationship between the client and clinician needs to be 
open, honest, and safe, allowing clients to voice their 
symptoms/side effects with psychotropics.
Cognitive difficulties have been noted in previous 
studies as a result of psychotropic medication use. In 
fact, Hellwell (2002) noted that many clients experience 
problems with cognitive abilities such as rigidity or 
dullness of thinking. These cognitive difficulties can 
contribute to psychotropic medication nonadherence, as 
well as confusion of regimes.
Physical aliments are identified in studies 
describing side effects of psychotropic medication use. 
Fincke, Miller, and Spiro (1998) note that clients 
reported an increase in physical illness while on 
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psychotropic medications, including, "nausea, 
indigestion, headache, blurred vision, dizziness, dry 
mouth, and itchy skin" (p. 184). Additional physical 
ailments discussed in the literature include psoriasis, 
acne, and hair loss. These side effects have been found 
among 45 percent of clients on a Lithium regime (Yeung & 
Chan, 2004). Hair loss has also been identified in 
studies of antidepressant use in adolescent quality of 
life (Cheung, Levitt, & Szalai, 2003) .
Relationship between Client and Clinician
Another barrier to medication adherence is the 
relationship between clients and their clinicians. 
Lindstrom and Bingefors (2000) noted that the attitudes 
of clinicians towards clients affects clients' adherence. 
Other factors that reduced medication adherence were the 
clinicians' "authoritarian attitude, aloofness, passive 
behavior, indifference, anger, denial, cynicism, 
hopelessness, and ignorance" (Lindstrom & Bingefors, 
2000, p. 113). Kerse et al. (2004) studied medication 
adherence in comparison with physician/patient 
relationship and discovered that "trust and 
physician/patient concordance were significantly related 
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to compliance" (p. 455). These findings suggest that 
improving the relationship between clients and their 
clinicians can have long-term effects on medication 
compliance (Kerse et al., 2004).
Treatment
The treatment of SPMI includes psychosocial therapy, 
pharmacotherapy, and dual-modality services (i.e., a 
combination of the two) for. clients. Evidence-based 
practice finds that a dual-modality approach to SPMI 
clients increases psychotropic adherence (Bentley, 
Rosenson, & Zito, 1990). Pharmacotherapy includes oral 
and intramuscular psychotropic medications. Psychotherapy 
utilizes individual and group therapy typically 
psychoeducational in nature to promote insight. Smith,' 
Birchwood, and Haddrell (1992) noted that many SPMI 
clients lack knowledge about psychotropics, which can 
lead to lowered adherence rates.
Psychosocial Rehabilitation
Psychosocial rehabilitation (i.e., psychoeducation) 
targeted to SPMI clients regarding drug regimes, illness, 
and side effects can help increase insight. Yet, mixed 
findings exist. Increased insight can improve clients' 
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medication adherence. However, studies that base 
interventions in psychosocial rehabilitation, without 
utilizing additional facets to assist clients, fall short 
of the goal of increased psychotropic adherence (Hayward 
& Chan, 1995; Kavanagh, Duncan-McConnell, Greenwood, 
Trivedi, & Wykes, 2003; Smith et al., 1992).
Assertive Community Treatment (ACT) is an "intense 
mental health program model in which a multidisciplinary 
team of professionals serves patients who do not readily 
use clinic-based services, but who are often at high risk 
for psychiatric hospitalization" (Bond et al., 2001). ACT 
has been found to increase medication adherence among the 
homeless population. Dixon et al. (1997) studied a group 
of homeless individuals who voluntary received services 
from a clinical team that employed the ACT program. The 
results of this treatment modality included rapid 
increase in medication adherence among the homeless 
population, as well as fewer psychiatric symptoms (Dixon 
et al., 1997).
Pharmacotherapy
Many interventions targeted for SPMI clients include 
pharmacotherapy. Psychotropic adherence is a main concern 
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for many clinicians working with SPMI clients, as 
re-hospitalizations are costly to the public. Many 
studies analyze tactics for increasing psychotropic 
adherence. Love (2002) investigated the strategies 
employed to increase medication adherence and noted that 
depot psychotropic medications (i.e., intramuscular 
injection of a psychotropic medication) utilized with 
non-adherent clients were more effective when combined 
with social support. He also found that atypical 
psychotropics (i.e., second-generation anti-psychotics) 
with improved efficacy and tolerability, increased 
adherence and reduced hospitalizations compared to the 
depot and oral medications (Love, 2002). Love's (2002) 
findings should be heeded as a significant number of 
hospitals and community mental health centers are being 
sued for incompetence, neglect, and even abuse in 
relation to clients'' adherence to psychotropic medication 
(Gerhart & Brooks, 1983).
Dual-modality Interventions
Programs that utilize a combination of psychosocial 
rehabilitation and pharmacotherapy have significant 
results in regards to increased psychotropic adherence.
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Ho et al. (1999) utilized psychoeducational groups to 
increase clients' insights into their illness and 
psychotropics, employing the ACT program that "enhanced 
the engagement process by maximizing patients' access to 
social and rehabilitative resources" (p. 17 68).. The 
results of Ho et al. (1999) included increased engagement 
rates, fewer hospitalizations after entering the ACT 
program, and abstinence from illicit drugs (measured by 
urine toxicology).
Utilization of dual-modality treatment markedly 
increased rates of psychotropic adherence for clients 
with chronic mental illness. Azrin and Teichner (1998) 
utilized family support and psychoeducation to increase 
adherence rates. They utilized a control group and an 
experimental group, where the control group received 
information based solely on the medication, and the 
experimental group received an in-depth educational 
program that included the client and the family receiving 
information about the drug regime. The program increased 
adherence to 94 percent in the. experimental group, 
whereas the control group's rate of adherence was 73 
percent (Azrin & Teichner, 1998).
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Skinner (2005) worked with the mentally ill homeless 
population by employing psychoeducation and a program 
that he termed Modified Therapeutic Community (MTC). MTC 
is similar to ACT, where clients' individual treatment 
plans revolve around psychosocial rehabilitation, 
support, and pharmacotherapy. Skinner (2005) utilized a 
quasi-experimental design and compared the MTC group to a 
group of homeless individuals at a general shelter. The 
general shelter did not incorporate all the needs of the 
client, only housing. The MTC experimental group had a 
significantly lower percentage of individuals 
hospitalized and/or transferred to a high level of care 
facility when compared to the population in the general 
shelter. Skinner's (2005) MTC group also had higher rates 
of medication adherence compared to the control group 
(81.4% versus 64.7%, respectively).
Theories Guiding Conceptualization
There are several theories discussed in the 
literature regarding medication adherence. Social 
learning theory is based on behavioral theories that 
focus on observable behaviors, rather than internal 
motivations, needs, and perceptions of individuals
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(Zastrow & Kirst-Ashman, 2004). Social learning theory­
focuses on behaviors and how these are learned. It 
assumes that behaviors can be changed with positive . 
reinforcement (Zastrow & Kirst-Ashman, 2004). Social 
learning theory includes a "positive orientation to 
treatment that attempts to build patients' 
self-awareness, awareness of others, and coping skills" 
(Bedell, Hunter & Corrigan, 1997). Studies that utilize 
any form of psychosocial education to increase clients' 
insight are employing social learning theory (Hayward & 
Chan, 1995; Kavanagh et al., 2003; Smith et al., 1992).
Another theory that has guided research in this area 
of study is compliance theory. Compliance theory is a 
health-belief model asserting that:
individuals will take action, seek care and 
comply with health regimes if they regard 
themselves as being susceptible to the 
condition in question, if the condition has 
serious consequences, if the action would be 
beneficial and if they feel that the barriers 
to action are outweighed by the benefits 
(Lindstrom & Bingefors, 2000) .
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This model utilizes sociodemographic factors, 
particularly education, when describing behaviors 
(Lindstrom & Bingefors (2000) . Behaviors are influenced 
by the perceived severity of illness and benefits of 
medication, as well as barriers. Rietveld and Koomen 
(2002) describe the health belief model in terms of seven 
determinants of compliance behaviors: "when pain would 
remit, the cause of pain, the mysterious nature of pain, 
how pain alters life style, personal control of pain, 
regarding blame for pain, and whether pain is experienced 
constantly of intermittently" (p. 625). Psychosocial 
rehabilitation addresses self-determination through 
social skills group training, which can lead to increased 
adherence, the ultimate goal of many research projects.
The theory guiding this research project is 
client-centered theory. Carl Rogers developed this theory 
from his self-theory describing a person as the result of 
his/her experiences and how he/she perceives those 
experiences (Zastrow & Kirst-Ashman, 2004). This theory 
focuses on the "way of being" with the client, as opposed 
to the "way of doing" things for.the client (Corey, 
2000). Corey describes the sense of trust that enables 
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the client to move forward and grow (2000) . Faith in the 
person is one of the basic premises of this theory, the 
faith that each person can be trusted (Corey, 2000) . This 
research project aims to understand client nonadherence 
to medication while increasing trust between clinicians 
and clients. The conceptual framework of the 
client-centered theory is that clients will become more 
honest with clinicians once they feel that they are 
understood and respected by those same clinicians 
(Thorne, as cited in Corey, 2000).
Summary
This chapter discussed severe and persistent mental 
illness, as well as outlines the costs (direct and 
indirect) involved in serving individuals with SPMI. 
Barriers to medication adherence are discussed in detail 
as well as the different treatment modalities utilized 
with this population. Psychosocial therapy based 
interventions are discussed in terms of improving 
medication adherence and insight into illness. 
Interventions based solely on pharmacotherapy and 
dual-modality interventions, those that combine 
psychosocial therapy and medication to assist SPMI 
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clients is discussed. Finally, the theories guiding this 





This exploratory study was conducted using both a 
qualitative and quantitative measurement method to 
explore, from the clients'' perspective, barriers to 
psychotropic medication adherence. This chapter will 
discuss the study design, sample from which data was 
collected, method and instrument used for data 
collection, data analysis, and procedures taken to 
protect confidentiality and anonymity for human subjects 
in this study.
Study Design
The purpose of this study was to explore the 
barriers that cause psychotropic nonadherence in 
individuals with severe and persistent mental illness 
(SPMI). Clients were encouraged to share information in 
relation to their experiences with psychotropic 
medication regimes during a semi-structured, one-on-one 
interview. The interviewer administered the study 
questionnaire that included both a quantitative and a 
qualitative component. The demographic component 
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contained information such as; age, gender, number of 
hospitalizations, diagnosis, etc., while the qualitative 
portion explored barriers to psychotropic adherence from 
the client's perspective, through open-ended questions.
Methodology implications for this study are based on 
the guiding principles of the psychosocial rehabilitation 
and recovery model. These principles promote 
self-determination by supporting persons with SPMI, 
encouraging them to make their own choices, and involving 
clients in their own treatment planning. By providing 
individuals with the opportunity to express their own 
needs and desires, mental health workers minimize 
professional distance and create empowering adult-to 
adult relationships (Ragins, 1994).
Clients may have benefited from participation in 
this study by learning the importance of self-advocacy, 
enhancing self-esteem, and understanding the importance 
of mutual working relationships with mental health 
professionals. This project was an exploratory study of 
barriers to psychotropic adherence from the client's 
perspective. By inviting individuals to voice their 
mental health concerns, this study supported•the consumer 
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movement motto: "Nothing about us without us" (National 
Mental Health Association, 2005).
Limitations
There are several limitations of this study. Social 
desirability, answering questions in the direction of the 
interviewers perceived needs or wants, is unavoidable in 
this study due to the design. Nancarrow and Brace (2000) 
examined the causes of social desirability bias (SDR), 
ways of detecting bias, and techniques used to reduce the 
problem. They concluded that there is no way to reduce or 
eliminate social desirability because establishing that 
it actually took place is difficult.
A second limitation is use of a non-standardized 
instrument. A standardized instrument addressing 
medication nonadherence from the participant's 
perspective could not be located. Researchers designed a 
questionnaire (Appendix A), specific to this research, 
for the interview process. To ensure content validity, 
researchers conducted a two-phase pretest.
Phase one, employed mental health professionals 
(i.e., case managers), serving individuals with SPMI, to 
review the interview.questionnaire and provide.critical 
feedback. This segment of the pretest identified poorly 
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worded interview questions, questions revealing the 
researcher's bias, and culturally sensitive wording. 
Phase-two tested the interviewer's ability to deliver the 
study instrument effectively. Case managers were given a 
questionnaire to score the wording of questions, the 
interviewer's ability to communicate clearly, and the 
interviewer's approach to the interview process (Berg, 
2004, p. 90). Additionally, the pretest provided 
researchers with the opportunity to test the interview 
environment and determine the duration of the interview 
and debriefing process.
The final limitation in this study is a result of 
purposeful sampling. Because this study addresses a 
specific problem, within a distinct population, purposive 
sampling requires that participants have certain 
characteristics in common in order to be selected for an 
interview. The selection criteria for this study included 
persons' with a SPMI, receiving mental health treatment 
from the AB2034 program, male and female, and a minimum 
of 18 years of age. Furthermore, external validity is 
limited because the participants are from one agency; 
making it difficult to generalize study findings.
Notwithstanding these limitations, this exploratory study 
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provided valuable insight to psychotropic nonadherence 
from the most reliable source, individuals diagnosed with 
a SPMI.
Sampling
A simple random sampling of participants consisting 
of, males and females at least 18 years of age, diagnosed 
with a SPMI or co-occurring disorder (COD), i.e., mental 
disorder and substance use was employed(DHHS Publication 
No. [SMA] 05-3992, 2005). These individuals are currently 
receiving intensive recovery services through the AB2034 
program at the Mental Health Association of Orange 
County, California. Of the 99 clients currently enrolled 
in the AB2034 program, this study included 16 individuals 
as participants.
To select a sample of 16 individuals, each client 
was first assigned a number between 1 and 99. Using a 
table of random numbers (Appendix B), researcher will 
picked any point on the table, reading across the rows, 
or down the columns, writing a list of the first 16 
numbers found. These 16 numbers identified the 16 
participants that made-up the- sample for this study. Each 
person selected for the study was provided with a
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recruitment flyer, hand delivered by his or her case
J
manager, which provided information such as the time, 
date, and possible benefits for participating in the 
study (Appendix C). Next, identified participants were 
then phoned by the researchers and asked if interested in 
participating in this study.
Permission to conduct this study was granted after 
review of the project proposal by Keith Parker LMFT, 
AB2034 Program Director for the Mental Health Association 
of Orange County, California.
Data Collection and Instruments
The survey instrument was a 10-item, one-to-one, 
semi-structured interview. Open-ended questions were 
designed to generate possible reasons for psychotropic 
nonadherence. Examples of interview questions included, 
"Can you tell me why you take medications?"; "Do you 
believe it is your decision alone to take medications? 
Who do you believe makes this decision?" and "How have 
medications helped you". Examples of demographic 
questions included, "What is your currently living 
situation?"; "What is your diagnosis?" and "Including all 
mental health agencies, how long have you been receiving 
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mental services?" Both components of this study, 
demographics and qualitative interview, use a nominal 
level of measurement.
Due to the lack of qualitative studies on 
psychotropic adherence, this questionnaire was uniquely 
designed to explore possible barriers to adherence, from 
the participant's perceptive. To ensure content validity, 
this study instrument was designed based upon previous 
studies cited in the literature review.
Procedures
Data collection took place on Fridays between the 
hours of 8:00 a.m. and 3:00 p.m., over a period of 
two-weeks. Interviews were held at one of the Mental 
Health Associations of Orange County's clinics. To ensure 
confidentiality, interviews were conducted in a private 
office. Interview sessions range from 15 - 40 minutes.
A Mini Mental Status Exam (MMSE) (Appendix D) was 
administered to individuals interested in participating 
in this study. The AB2034 Program Director, a Licensed 
Marriage and Family Therapist (LMFT), agreed to perform 
the MMSE on each person wishing to participate. This 
measure was taken to ensure the individuals' cognitive 
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appropriateness to participate in the study at this 
particular time.
The LMFT administering the MMSE followed Folstein & 
Folstein's, suggested guidelines for scoring as noted at 
the bottom for the MMSE form. Participants scoring more 
than 21 points out of the maximum 30 point were invited 
to participate in the study. Participants scoring less 
than 21 points were not eligible to participate in the 
study due to mild-moderate cognitive impairments. 
Fortunately, no participants were turned away due to 
scores under 21 points. Participants received an envelope 
containing $15 cash in return for their time and effort. 
Upon receipt of the $15 cash gift for participating, 
participants were asked to sign a receipt form by placing 
an "X' in the box. This method of signature for receipt 
of funds was instituted to maintain the participant's 
privacy and to keep their information confidential.
All data and client information, MMSE, interview 
questionnaires, and interviewers' notes was contained in 
a locked file cabinet within the locked office of the 
program director.
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Protection of Human Subjects
Several measures were taken to protect the 
confidentiality of the participants in this study. All 
participants in this study were voluntary. The 
questionnaires used during the interview utilized an 
identification number rather than the participant's 
names. Informed consent (Appendix E) was obtained by 
using forms and procedures approved by the institutional 
review board. Documentation of informed consent was read 
aloud and explained to each participant. Participants 
agreeing to the study were asked to place an "X' in the 
box on the consent form labeled "YES". This method of 
identification and signature of consent was instituted to 
maintain the participant's privacy and to keep their 
information confidential. To maintain confidentiality, 
any documents containing participant information were 
only accessible to the researchers and their research 
advisor.
Participants were informed at the beginning of the 
interview that they did not have to answer any questions 
they believe to be too personal. Furthermore they were 
informed that they had the right to refuse answering 
any/or all questions without explanation or penalty. The 
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interviewer informed participants that the study was 
voluntary and that they could discontinue the interview 
and leave at anytime. Participants were informed of the 
confidential nature of their responses. At the end of the 
interview, researchers provided participants with a 
debriefing statement (Appendix F), which was read aloud 
and explained. Participants were informed of how they 
obtain study results and were provided with names and 
numbers of mental health agencies on the debriefing 
statement, in case participants became distressed.
Data Analysis
Qualitative data analysis was used for participant's 
responses to open-ended questions during a one-to-one 
semi-structured interview. Researchers identified 
cultural domains for participants' responses to all 
open-ended questions based on underlying association of 
content. The responses derived from this study could be 
used to create new treatment interventions and recovery 
planning.
Summary
This exploratory study used both a qualitative and 
quantitative measurement method to explore, from the 
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client's perspective, barriers to psychotropic adherence. 
This chapter discussed the study design, sample from 
which data will be collected, method and instrument used 
for data collection, data analysis, and procedures taken 
to protect confidentiality and anonymity for human 





This chapter describes the demographics for the 
study group using a quantitative method of data 
collection and the major themes that emerged using a 
qualitative method, open-ended questions, concerning 
reasons for psychotropic medication nonadherence. 
Verbatim responses from participants as recorded in 
one-on-one interviews are provided allowing consumers of 
mental health services a chance to be heard.
Presentation of Findings
Demographics for eligible participants consisted of 
16 adults receiving mental health services from the 
Mental Health Association of Orange County, AB2034 
Program. In terms of gender, 62.5% of the participants 
were female and 37.5% of the participants were male 
(Table 1). The mean age was 42.3 years old (Table 2).
The sample was composed of 50%. Caucasian., 18.8% 
Black or African American, 18.8% other of which one 
participant sincerely replied, "I am capital, NEGRO, 
Negro," and 12.5% of participants refused to answer the 
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question (Table 3). Of the 16 participants involved in 
the study, 50% were single/never married, 6.3% were 
separated, 37.5% reported being divorced, and 6.3% were 
widowed (Table 4). A majority of the participants 93.8% 
reported being unemployed (Table 5), while 31.3% reported 
having.a high school diploma or the equivalent, and 37.5% 
reported having some college or a two-year college degree 
(Table 6).
Within the past 12 months of administering the 
questionnaire, 12.5% of the participants stated that they 
had been hospitalized for psychiatric care, and 12.5% 
were incarcerated. Another 12.5% were both incarcerated 
and admitted to a psychiatric hospital, 6.3% were both 
incarcerated and received detoxification treatment for 
substance abuse, 6.3% received detoxification treatment 
for substance abuse only, and 50% reported no 
hospitalization, incarcerations, or substance use 
treatment (Table 7).
Participants were asked, "Including all mental 
health agencies, how long have you been receiving mental 
health services?" Findings declared that 6.3% had been 
receiving services for less, than 2 years, 25% stated 2 - 
5 years, 12.5% fell between 5-7 years, 12.5% claimed 7 
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- 10 years, and 43.8% said they had received services for 
more than 10 years (Table 8).
Finding permanent housing for persons with a severe 
and persistent mental illness can be challenging. 
However, this study revealed that 56.3% of the 
participants live independently, meaning, they rent an 
apartment in the community. Furthermore, 12.5% reside in 
sober living facilities, 6.3% live with family members, 
6.3% stated other living arrangements (possibly a hotel 
room), and unfortunately 18.8% remain homeless (Table 9).
All participants in this study are diagnosed with a 
severe and persistent mental illness (SPMI) and 
diagnostic types were not reported. Self-reported 
diagnosis included 31.3% Schizophrenia, 31.3% Bipolar 
Disorder, 12.5% Schizoaffective Disorder, 6.3% Major 
Depressive Disorder, and 18.6% reported multiple 
diagnosis with conflicting diagnostic criteria (Table 
10) .
Using the most recent clinical documentation 
reported by the clients' attending psychiatrist and 
participants' self-reports, 31.3% of the 
client/psychiatrist diagnoses matched, 31.3% did not 
match, and 37.4% matched part of the reported diagnosis, 
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but not the complete diagnosis. These findings lead to a 
comparative analysis of clients' self-reported medication 
regimen versus the psychiatrists' documentation of 
prescribed psychotropic regimens.
The comparison of clients' self-reported 
psychotropic regimens versus psychiatric records revealed 
that 31.3% of the clients had accurately stated their 
prescribed medication, of which 31.3% reported completely 
different psychotropic medications than documented by 
their psychiatrist; 31.3% reported some of the same 
medications as were documented, but not all; and 6.1% 
reported taking psychotropic medications while their 
records indicated that they were no longer receiving 
pharmacotherapy treatment.
Participants were asked the same questions, in the 
same order. Each set of questions were designed to 
illicit reasons for adherence/nonadherence to 
psychotropic medication regimes from the participants' 
perspective. Several content categories emerged from the 
participants' verbatim responses, some of which will be 
provided to illustrate the nature of their concerns.
The first set of questions explored current use of 
psychotropic medications and their perceived benefits, if 
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any. "Are you currently taking medications for a mental 
illness?" Which was followed by one prompt, "Pills or 
shot?" All participants said they were currently taking 
medications, of which 93.7% stated they were taking their 
medication in pill form and 6.3% said by shot. Given the 
severity of the participant's mental illnesses, and the 
high rate of psychotropic nonadherence within this 
population, researchers suspect some level of social 
desirability effect.
The next was, "Can you tell me why you take 
medication?" Nearly 70% (68.8%) of the participants 
stated that they took psychotropic medications to address 
symptoms caused by a mental illness, while 31.2% simply 
stated that they took the prescribed medication because 
they were diagnosed with a mental illness. One of the 
participants responded to this question by saying, 
"Because I have racing thoughts, unable to sleep, massive 
mood, swings, violent, quite the shopper when not on 
medications." Another participant responded by saying, 
"Because I have been diagnosed with schizophrenia in 
1990."
This question was followed by one prompt: "How have 
medications helped you?" Once again the majority, 68.4%, 
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stated that medications helped to reduce, symptoms, 21% 
reported increase ability to function in daily 
activities, 1% found the medications non-effective, and 
1% did not have an understandable response. A participant 
that believed medications helped reduce symptoms said, 
"Helps me to sleep, helps me when I hear voices, when I 
do not take them I get depressed, it stabilizes my mood." 
A participant that reported an increase in functioning 
stated, "Helps a great deal, helps me function, even 
though I do not have a job or anything constructive, I 
can get the basic needs: food, not afraid to deal with . 
social environment." The participant that found 
psychotropic medications ineffective responded by saying, 
"I do not really feel a difference, but I do not feel 
mentally ill either."
When asked, "Tell me reasons why you do not like 
taking your medication?" 72.7% of the participants stated 
they did not like taking psychotropic medications due' 
negative side effects, 9.1% identified feelings of 
depersonalization, 9.1% found psychotropics inconvenient, 
and 9.1% said the medications were ineffective. One of 
the clients concerned with negative side effects stated 
that the medication, "Make me feel sick and very sleepy 
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or worse than I am feeling." The participant expressing 
feelings of depersonalization replied, "Makes me feel 
different at times, different than other people, I feel 
ok and if I continue the medications it might induce 
something to make it worse." Another participant stated 
that taking medications were inconvenient, "Cuz it's a 
hassle to take them, remembering to take them." 
Ineffectiveness was expressed as, "One reason, it doesn't 
help much. I am kind of scared of them too, they may hurt 
my body."
The following prompt was asked after the previous 
question to evaluate participants' willingness and/or 
opportunity to seek help to manage medication regimens: 
"Have you talked to anyone about this?" Most of the 
participants (66.7%) said that they had talked to 
someone, 25% stated they had not talked to anyone, and 
8.3% stated that they attempted to talk with someone. One 
of the participants said, "Yes, 1 talk to other clients 
and doctor." Another client attempted addressing 
medication concerns stated, "Try to talk to doctor about 
it, yet we do not have anytime. But I would like to."
The next set of questions deal with the 
participants' environment, relationships, illicit drug 
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use, and mental health services they may have received or 
would like to receive.
The first question was, "Can you remember a time 
when you decided not to take your medications?" The 
response was almost split evenly: 56% replied, "yes", 
while 43.7% relied "no." The follow-up probing question 
was then asked of all participants: "Can you tell me what 
was going on in your life at this time?" Active 
psychiatric symptoms were reported by 75% of the 
participants. One participant stated, "I was religiously 
preoccupied, had the desire to be functionable without 
medication. Spiritually I felt I had to be off 
medications, I don't feel that way now, voices were being 
crafty, evil voices telling me to take the medications, 
anyone would be scared." Furthermore, 12.5% reported 
physical aliments, and 12.5% reported being in denial of 
having a mental illness.
The following question asked participants to discuss 
their opinion of their psychiatrist: "How do you feel 
about your psychiatrist?" The vast majority, 72.2%, had a 
positive response such as, "I like him, able to 
communicate. He has respect for me." While 27.8% had a 
negative response such as, "He does not say too much. He 
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prescribes meds, get therapy elsewhere. Pretty much 
in-and-out."
Seeking concreteness, the following probing question 
was asked of all participants: "How do you expect your 
psychiatrist to treat you?" An appraisal of the 
participants' responses resulted in 40% stating that they 
wanted to be treated professionally, as interpreted by 
one participant's reply, "With a firm hand, he is very 
good." Another 25% said that they expected to be treated 
respectfully by their psychiatrist: "With respect, just 
as I respect him." Furthermore, 25% wanted their 
psychiatrist to engage in active listening: "Be a bit 
more flexible about lowering the dosage or not taking 
certain medications. He wants me to take more to get rid 
of the voices. I do not want to take Zyprexa because of 
the side effects." Finally, 10% of the respondents said 
that they wanted to be treated compassionately, simply 
stated as, "Kindly."
The following questions were asked to explore the 
possibility of participants engaging in self-medication 
practices using illegal drugs. When asked, "Was there 
ever a time in your life when you used substances such 
as; alcohol, cocaine, marijuana, methamphetamines, 
49
heroin, etc., instead of your medications?" About (43.7%) 
said, "Yes" and 56.3% said, "No." Once again, researchers 
believe there to be some element of social desirability 
in the participants' responses because most of the 
clients enrolled in the program surveyed have 
co-occurring disorders.
Of the participants who stated they had used illegal 
drugs, a probing question was asked: "Can you tell me why 
you decided to do illegal drugs instead of taking your 
medication?" 38.6% said they took psychotropic drugs to 
reduce psychiatric symptoms: one participant said they 
used illegal drugs due to, "Depression." Furthermore, 
23.1% replied similarly stating they wanted to feel 
different: "T wanted to a different feeling over my body 
and mental status." Another 23.1% stated other reasons 
for using such as concurrent use: "I used cocaine and 
meth and marijuana but not instead of [my prescribed 
medication]." In addition, 7.6% faulted their current 
living situation for taking illegal drugs instead of 
their prescribed medications: "Partly environment, 
homeless...." Lastly, 7.6% stated boredom as a reason for 
using illegal substances, "... bored, being poor you have.
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nothing to do, so you take drugs offered to you for 
free. "
The next question attempted to identify the mental 
health services that participants believed to improve 
their quality of life: "Thinking about the mental health 
services you have received, what services do you believe 
have most improved your quality of life?" The 
participants' responses were diverse for example, 22.7% 
said that their relationship with their mental health 
worker improved their quality of life: "... I have a really 
good counselor." Another 18.2% stated that psychotropic 
medications played an important part of their recovery. 
One participant provided a powerful illustration of their 
perceived benefits of psychotropic medications: 
"Medications, without it I would be starving myself out 
on the street, cold, voices tell me to leave even if I 
had a home, don't wear warm clothes, don't eat, don't 
move, keep walking forever." Several other services were 
mentioned: group therapy (18.2%), individual therapy 
(13.6%), educational services (9.1%), food (9.1%), and 
housing (9.1%). The following statements further 
exemplify services the participants found useful: "The 
food, housing, computer room for school and stuff, 
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therapy women's group." "Having my own place at an 
affordable rate, Section 8 housing way below monthly rate 
of rent. Inspections to help get our place more 
organized." And, "Therapy, talking and the medications, 
having a place to come to, to focus' on staying healthy 
mentally."
The final question, followed by two probing 
questions, revealed from the participants' perspective 
who they believed controls their decision to take 
psychotropic medications or not. Beginning with: "Do you 
believe it is your decision alone to take medications?" 
Of the 16 participants, 62.5% answered, "No," while 37.5% 
answered, "Yes."
Of those participants who believed it was not their 
decision alone whether or not to take medications, the 
following probing questions were asked: "who do you 
believe makes this decision?" followed by, "Can you tell 
me more about that?" Sixty-percent of the respondents 
believed it to be the doctors' decision alone whether or 
not they needed to take psychotropic medications, while 
20% stated it was their choice together with their 
doctor, and 20% said it was a combination of themselves, 
their doctor, and society.
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Whether or not participants believed it was their 
decision to take medications, the doctors, or society, 
they were given the opportunity to explain their 
responses when asked, "Can you tell me more about that?" 
Participants' verbatim responses were as follows:
• "I feel he knows the best about the medications 
and what it can do for my mental illness."
• "It needs to be a joint decision, they have the 
knowledge, I have the job of giving approval so 
I can get better."
• "I don't know how to elaborate."
• "My mind is not ready to make decisions on my
own about medications."
• "Too little time in the office, I would like a 
half-hour to lye on couch."
• "I take it. I stay on my path of education and 
a good job. If I don't take it, I relapse. I do 
not want to go through that again. I am 
thankful for the chance."
• "Because in order to receive SSI you must be 
following a plan, not taking meds can take you 
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off SSI. The doctor can put you in the hospital 
to get you regulated when you do not comply."
• "Because I tell him the medicine is too strong, 
he tells me to take it anyway. I will reduce 
the dose, pill down to 4 to 6 parts."
• "I need medication. I went for a physical they 
told me to see a psychologist. Then they sent 
me to a psychiatrist for medication. That is 
why I think that."
• "Society can interfere by telling doctors, 
people, the law, we are being out of control 
and give me a diagnosis."
• "He knows what I need for my mental problems, 
what type of medication."
• "I have struggled with mental illness 4 years 
and voices off and on medications. Off meds I 
talk to myself, yelling, relationship with 
society strained, people think I'm crazy. I 
regret what I have said during times I am off 
medication and behavior. Experiencing time 
without meds make me understand that I need it 
and helps me set the right dosages. I used to 
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sleep all day, eat all day, get fat, state of 
incapitation. It was torture, so I went off."
Summary
This chapter reviewed the results of this research 
project derived from participant's verbatim responses 
conducted through one-to-one interviews. Data was 
obtained from individuals diagnosed with a severe and 
persistent mental illness and substance use disorder in 
an attempt explain barriers to psychotropic adherence 
from the client's perspective. Three themes were found 
that might cause barriers to psychotropic adherence; 






This chapter will discuss the results of this, study 
and how they are essential to the understanding of 
clients and their adherence or nonadherence to a 
medication regime. It will also discuss the limitations 
of the study. This chapter will also provide 
recommendations for social work practice. This chapter 
will close with a final conclusion of the section.
Discussion
Due to the nature of this exploratory study and the 
use of a non-standardized instrument, the researchers 
utilized frequencies to■identify significant results. The 
percentages were calculated for each question. The 
calculations were utilized to identify any relevant 
themes noted in the participant responses.
All participants revealed that they were in fact 
taking psychotropics for a- mental illness. Over 90 
percent of the participants were taking pills, leaving 
less than 10 percent currently taking a shot to deal with 
a mental illness. Even this first question leaves the 
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researchers in a quandary. Social desirability was 
believed to affect at least one participant in how they 
answered because they recently had their psychotropics 
revoked to determine if the identified symptoms were in 
fact from a mental illness or due to illicit drug use. 
The reasoning behind most of the participants having 
pills prescribed is cost. It has been noted to the 
researchers that for a client to have monthly injections, 
the cost would soar to over $2000.00. The pills are 
cheaper and do not require a doctor visit to administer 
the medications.
In this study, several themes were found to affect 
adherence to a psychotropic regime. Insight., side 
effects, and relationship between client and clinician 
are a few of the themes identified during the one-on-one 
interviews with clients suffering from SPMI.
Insight
In response to the question of "Why do you take 
medication?" 68.8 percent of- the participants described 
reduction of symptoms from the mental illness (i.e., 
voices lessened, less racing thoughts, etc.). The 
researchers accepted these types of responses as an 
indication of client insight into their mental illness 
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and symptomotology. The remaining 31.2 percent of 
participants taking psychotropics do so due to a 
diagnosis of a mental illness. The participants appeared 
to understand why they take psychotropics, yet they did 
not altogether understand their diagnosis or psychotropic 
regime.
Less than one-third (31.3%) of the clients surveyed 
were aware of their diagnosis. This means that 68.7 
percent of the clients surveyed were unaware of their 
current diagnosis. This statistic suggests lack of client 
insight which can affect their adherence/nonadherence to 
a medication regime. If the clients do not know their 
diagnosis, how can they possibly understand what they 
need to do to help themselves recover? Seedat et al. 
(2002) noted that lack of education is associated with 
medication nonadherence. In fact, these authors stated 
that clients are poorly informed of their diagnosis and 
treatment.
Another question that identifies lack of insight is 
the medication regime identified by the participant. The 
researchers, after conducting the interviews, reviewed 
the clients' files to ascertain whether they had answered 
these two questions correctly. Again, less than one-third 
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(31.3%) of the clients reported the correct medication 
regime that they were currently prescribed. This leaves 
68.7 percent of participants unaware of their current 
medication regime. The participants do not understand 
what they had been prescribed or their current diagnosis. 
This can be seen as the lack of insight into mental 
illness and/or denial of diagnosis. Yet it can be also 
seem as a problem with the doctors and how they discuss 
the mental health diagnoses and how medication can help. 
Clients need to be informed about their illness and 
medication regime to increase psychotropic adherence.
As the interviews continued, it was noted that 
clients claimed to continue taking medications despite 
effective elimination of symptoms. Many clients reported 
decreased symptoms, but increased side effects (i.e., 
sleepy, not hungry, too hungry, etc.). Most (72.7%) of 
the participants reported talking to friends and family 
about their side effects, 25 percent reported not talking 
to anyone, and only 8.3,percent of participants who 
attempted to talk to their doctor. If participants are 
getting information about side effects, mental illness, 
and medication from friends and family, they are 
overlooking the one individual that has the knowledge and 
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ability to help them: the clinician. If clients are 
seeking information from the clinician, insight into 
their mental illness, symptoms, side effects, and 
alternative treatments can be discussed in detail.
Side Effects
When the participants were asked why they did not 
like taking their medications, almost three quarters 
(72.7%) noted side effects. Another 9.1 percent noted 
feelings of depersonalization as the reason for not 
taking the medications. Other responses included 
inconvenience and ineffectiveness.
The next question was posed to have the participants 
speculate on why they might not want to take medications. 
When the same participants were asked why they might not 
want to take the medications, many answered side effects 
(50%). Another 20 percent noted increased symptoms as the 
sole reason. The last 10 percent of participants 
demonstrated increased, insight into psychotropic regimes 
when noting a fear of addiction. Due to the design of 
this study, the exact side effects were not identified. 
Many clients may have felt embarrassment and chose not to 
describe the sexual side effects as a reason for 
nonadherence. Many clients noted the sleep side effects 
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(whether too much or too little) and the weight gain. 
Green et al. (2000) stated that psychotropics used to 
treat schizophrenia have been linked to weight gain. 
Clients appear well aware of these side effects. In the 
future, the researchers would design the next 
questionnaire to more fully identify the exact side 
effects experienced by each participant. 
Relationship between Client and Clinician
A close working relationship between client and 
clinician is helpful in addressing adherence/nonadherence 
to treatment plans utilizing psychotropics. The 
participants were asked if they had talked to anyone 
regarding the reasons why they do not like taking 
medications. This question not only suggested clients' 
insight into their mental illness, but also the quality 
of their relationship with their clinician. As stated 
before, over one-half (66.7%) of the participants stated 
that they talk to their family and friends, another 25 
percent revealed they do not talk to anyone, and only 8.3 
percent of the participant's reported attempting to talk 
to their doctor. Participants felt that their clinician 
did not listen to their concerns, telling them to 
continue on the same path. The responses to this question
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are telling in that participants would prefer to talk to 
friends and family versus talking to the doctor. 
Rosenberg et al. (2003) found that 50 percent of clients 
"never or infrequently" voiced concerns of side effects 
to their doctors. This suggests the importance of an 
open, honest, and egalitarian relationship between client 
and clinician.
The participants were also asked how they felt about 
their psychiatrist. Almost three quarters (72.2%) had 
positive feelings regarding their psychiatrist. The rest 
of the participants (27.8%) had negative feelings 
regarding their psychiatrist. Participants stated that 
they felt their psychiatrist was doing his/her job, yet 
the psychiatrist would not listen to the participants' 
concerns. Some examples of responses to this question 
include, "He doesn't listen," "He prescribes medications, 
get therapy elsewhere," and "I don't know■if he really 
listens."
Many participants felt that they were .not given 
enough time to talk to the psychiatrist. This could be 
due to the overwhelming case load' that the doctors are 
currently managing. The doctors do not have the time to 
go over each detail in a client's life. Yet, if the 
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client is to be involved in their own treatment plan, the 
doctors must divide time equally for clients so they have 
time to explain what they are feeling. Kerse et al.
(2004) noted that "trust" was significantly related to 
adherence. Improving the relationship between client and 
clinician can have long-term affects on medication 
adherence (Kerse et al., 2004).
The researchers then asked the participants how they 
expected their psychiatrist to treat them. Almost 
one-half (40%) wanted to be treated "professionally" by 
their psychiatrist. Being treated "respectfully" and 
using active listening skills were each represented by 25 
percent of the participants (i.e., 50% of total responses 
when added together). Another 10 percent wanted their 
psychiatrist to demonstrate compassion. Many participants 
feel they are not being treated as they should. If one of 
the precipitating factors in client adherence to a 
psychotropic regime is the quality of the relationship 
with their clinician, then we as a mental health field 
are failing to create an adequate, therapeutic and 
trusting working relationship with these clients.
Participants were also asked if it was their 
decision alone to take medications. About 63 percent
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(62.5 %) stated "no," and only 37.5 percent of 
respondents thought that it was their decision. The large 
percentage of participants stating that it is not their 
decision may suggest that many clients feel that they 
must take psychotropics to receive services for their 
mental illness, and they will take them even if the 
psychotropics appear to do nothing in terms of managing 
their symptoms.
Of the 62.5 percent who stated "no" to the above 
question, 60 percent believe that the doctor makes the 
decision to take medications, 20 percent believe that 
society makes that decision, and another 20 percent 
believe that they bear some of the decision making 
responsibility. This finding is troublesome as 
participants feel that it is not their choice to either 
take the medications or refuse them for a different 
treatment plan (i.e., alternative treatment plans that do 
not involve psychotropics). This finding may result in 
clients feeling disempowered, and perhaps even as if they 
are subjects of social control, and thus less apt to 
comply with their medication regimen.
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Self-medicating Behaviors
The researchers attempted to discover whether the 
participants had, in the past, utilized illegal 
substances instead of taking their prescribed 
psychotropic medications. Over one-half (56.3%) stated 
that they had never utilized substances instead of their 
psychotropics. This is another question for which 
responses may be influenced social desirability. Of the 
43.7 percent that stated that they had used illegal drugs 
instead of their psychotropics, over one third (38.6%) of 
the participants stated that the reason was to reduce 
symptoms. The other answers ranged from feel different 
(23.1%), environment (7.6%), and boredom (7.6%). Another 
23.1 percent of the responses were categorized as "other" 
as the respondents stated concurrent usage of drugs and 
psychotropics. Johnson, Brems, and Burke (2002) noted 
that 45 percent of substance abuse clients also had a 
mental disorder indicating the'difficulty of separating 
these two issues.
The researchers have working relationships with most 
of the participants in this study as interns at the 
AB2034 program. The researchers believe that the 
participants may have wanted to keep their drug use 
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private so that they would not lose services of the 
program. This seemed apparent in many answers to survey 
questions. The researchers needed to address 
confidentiality several times during interviews as 
clients struggled with telling their whole story. For 
example, when a participant was asked what type of 
medications s/he was currently taking, s/he asked "Who is 
going to see this research?" The researcher assured the 
participant that s/he would riot be identified as there 
were no names included in the study results. In fact, the 
doctors would not know who had participated in the study.
Limitations
The first and foremost limitation of this study is 
its sample size. Due to the nature of this exploratory 
study, the researchers limited the- participants to fewer 
than 20. The researchers conducted one-on-one interviews 
with each participant. Before the interview could begin, 
the participants were required to pass a mini-mental 
status exam performed by the program manager. If the 
study had been given unlimited time and resources, all 
100 clients in the AB2034 would have been interviewed.
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Due to the limited size of the sample, generalizing the 
findings to the rest of this population is difficult.
The second limitation concerns the nature of this 
exploratory study. There are limitations in terms of the 
participants self-reporting. In many cases participants 
will not report honest answers to the researchers for 
several different reasons. One, despite numerous 
assurances of confidentiality, the respondents may have 
been concerned that some of their responses could be 
later traced back to them, and their continued 
participation in the AB program would have been 
j eopardized.
This aspect may have led at least some participants 
to answering some questions, in a social desirable 
fashion. Participants may also have been concerned with 
telling everything to the researchers due to the 
researchers and respondents having a current working 
relationship. And, some participants may have been 
concerned with the embarrassment, shame, and stigma 
attached to reporting certain behaviors, such as illicit 
drug use.
Another limitation to this study was the design of 
the questionnaire. This study is unique as the 
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researchers wanted to tap into the participants' reasons 
for psychotropic adherence/nonadherence. The lack of a 
standardized questionnaire led the researchers to create 
the questionnaire based on their ideas gathered from 
existing research. Once the interviews began, the 
researchers identified several questions that they would 
either change or eliminate altogether. Some questions 
were designed to elicit a particular response, yet the 
question was unfortunately designed to be answered with a 
yes/no response. This limited the data collected on 
several respondents. An example of this is the question, 
"Can you tell me what was going on in your life at that 
time?" Many respondents answered that question with a 
"no".
The final limitation to this study was noted by the 
researchers, in that all the participants were recruited 
from the same agency. This fact makes generalizing the 
findings to other similar agencies difficult, as well as 
to the entire population of clients with SPMI.
Recommendations for Social Work
Practice, Policy and Research
The available research that is written on 
adherence/nonadherence to psychotropic regimes is based 
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solely on quantitative data collection and analysis. This 
qualitative project solicited responses from the 
participants' viewpoints, asking them exactly what they 
felt instead of having them select their responses from a 
list of answer options. This gave the participants the 
opportunity to voice their concerns in their own words. 
This study is unique in that the participants were 
permitted to state anything that they saw necessary to 
further explain their answers. The answers were written 
verbatim during each interview. The use of a tape 
recorder may have helped reduce the time of each 
interview as the researcher had to ask the participants 
to give them additional time to record their responses. 
This may have altered the results, as the participants 
may have lost their train of thought, however to what 
degree we cannot be certain.
Clear explanations could have been useful to the 
participants in terms of the guidelines for accepting 
services from the AB2034 program. Many participants may 
have altered their answers to cover up any undesirable 
behaviors that could eliminate them from the program in 
their perception (i.e., illegal drug use, nonadherence to 
treatment plan, and negative thoughts about the program).
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The study would have been best performed if no one 
working in the agency knew which respondents 
participated, attempted to participate, or were asked 
questions about the study. The study could have been 
performed in the privacy of the participants' home, 
utilizing personnel to perform the mini-mental status 
exam that had no knowledge of the participant or history. 
This may have helped the participants to answer questions 
in a safer environment, as no one knew them or could 
affect the services they receive from the program.
Another conclusion drawn from this study is that 
clients must be better informed about their diagnosis and 
medication regimes. This idea supports the psychosocial 
model of rehabilitation. If a client understands what 
they have been diagnosed with and how the psychotropics 
affect their body, the client will have more insight into 
their illness. Client insight provides for more effective 
self-determination. If the doctor and case managers spent 
more time educating the client about his/her illness, 
this would conceivably produce a more informed consumer 
and foster a more positive working relationship between 
client and clinician, which is integral to a client's 
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adherence to a treatment plan, which many times rely on 
psychotropics.
The client would also have the requisite knowledge 
to decide which medication they would like to try based 
on more than just rumors from other clients in the 
program. Perhaps then, clients may attain the type of 
egalitarian relationship with their doctor that will 
promote more equal decision making power, respect, and 
client self-determination. This egalitarian relationship 
is the key to recovery (Kerse et al., 2004) .
Our recommendations based on our findings are to 
include more psychoeducational training in the following 
areas: building more egalitarian clinician-client working 
relationships, disseminating information and ensuring 
clients' understanding of their diagnosis, mental 
illness, symptoms, symptom management, with clinicians 
striving to reduce the stigma associated with mental 
illness, and better educate clients about their 
medications, specifically how they work and why each they 




The purpose of this study was to examine barriers to 
psychotropic adherence/nonadherence from the client's 
perspective. This study examined the similarities between 
data collected utilizing quantitative measures and the 
data collected using the qualitative measures of this 
study. Interesting, the participants described many of 
the same barriers to psychotropic adherence as the 
current scholarly research. Participants described side 
effects, insight, self medicating behaviors, and 
relationship between client and clinician as the barriers 
they face while attempting to be psychotropic adherent.
Each of these factors are important to future 
studies, particularly from the client's perspective, as 
the latest model of recovery includes the clients as the 
experts into their own illness and recovery. The Mental 
Health Services Act (MHSA) is currently changing the face 
of mental health services to become more client and 
family centered. This study was a first attempt at 
starting the conversation about the need to create a more 
egalitarian working relationship between clients and 
clinicians to assist in the former's recovery.
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Additional studies should be conducted to replicate 
the findings of this project and be informed by these 
researchers' suggestions for an improved methodology.
When researchers asked the participants what has 
worked and did not work for them in recovery, new 
interventions can be created that can address the very 








This study was designed to give you, the participant, an opportunity to share 
your experiences with mental health services. I will read each question just as 
it is written, I can re-read the question if you do not understand it the first time. 
If you still do not understand the question, or you do not want to answer the 
question, for any reason, I will go onto the next question. Please take your 
time answering the questions. You may stop this interview at anytime. Are you 
ready for me to begin?
1. Are you currently taking psychiatric medications to address symptoms 
related to a mental illness?
If yes,
a. What type?
b. Pills or a shot?
2. Can you tell me why you take medication?
(a) Probing: How have medications helped you?
3. Tell me the reasons why you do not like taking your medication.
(a) Probing: Have you talked to anyone about this?
4. Can you remember a time when you decided not to take your 
medications? If yes,
(a) Probing: Can you tell me what was going on in your life at that time?
5. How would do you feel about your psychiatrist?
(a) Probing: How do you expect your psychiatrist to treat you?
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6. Was there ever a time in your life when you used substance such as; 
alcohol, cocaine, marijuana, methamphetamines, heroin, etc., instead of 
your medication? If yes,
(a) Probing: Can you tell me why you decided to do illegal drugs instead 
of taking your medication?
7. Can you tell me some reasons you might not want to take medications?
8. Thinking about the mental health services you have received: What 
services do you believe have most improved your quality of life?
9. What services do you believe would help people with mental illness have 
a better life?
10. Do you believe it is your decision alone, to take medication? Yes or No
(a) Who do you believe makes this decision?
(b) Probing: Can you tell me more about that?
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DEMOGRAPHICS
TODAY’S DATE: GENDER: (circle one) Male/Female
ID#: AGE:
MARITAL STATUS: (circle one) 





CURRENT EMPLOYMENT STATUS: 
(circle one)
1= Unemployed
2= Part-time (1-24 hours/week)
3= Full-time (25+ hours/week)
RACE: (circle one)
1= White/Caucasian
2= Black or African American
3= Hispanic or Latino
4= Asian
5= American Indian/Alaskan Native
6= Other






5= Board and Care
6= Room and Board
7= Sober Living Facility 
8= Other
IN THE PAST 12 MONTHS HAVE 
YOU BEEN/RECEIVED: (circle all that 
apply)
1= Hospitalized for Psychiatric Care 
2= Incarcerated (Jail or Prison)
3= Substance Detoxification
4= Substance Rehabilitation 
(in-patient)
5= Substance Rehabilitation 
(out-patient)
HIGHEST GRADE OR LEVEL OF 
SCHOOL
COMPLETED: (circle one)
1 = 8th Grade or Less
2= Some High School
3= High School Graduate or GED
4= Some College or 2-Year Degree 
5= 4-Year Degree
6= More Than 4-Year College Degree
CURRENT DIAGNOSIS:




4= Major Depressive Disorder 
5= Substance Abuse Disorder
6= Post-traumatic Stress Disorder 
7= Borderline Personality Disorder 
8= Other
INCLUDING ALL MENTAL HEALTH 
AGENCIES, HOW LONG HAVE YOU 
BEEN RECEIVING MENTAL 
HEALTH SERVICES:
(circle one)
1= Less than 2 year
2= 2 - 5 years
3= 5 - 7 years
4= 7 -10 years
5= More than 10 years




TABLE OF RANDOM NUMBERS
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Table of Random Numbers
Each value was randomly selected, with an equal chance of choosing any 





















2 97 60 74 43 80 79 45 69 7 59
3 52 24 47 70 ■ 6 67 2 27 80 65
4 14 75 8 43 71 61 41 87 19 22
5 75 74 10 49 '2 : 63 \ 46 - 93 22 98
6 30 42 60 87 33 47 85 36 67 69
7 87 42 93 20 ; 85 ■ 18 82 47 19 74
8 57 70 46 11 63 37 42 53 54 7
9 65 49 79 54 87 74 91 76 7 97 47
10 70 46 48 .22 37 94 45 1 88 31
11 21 62 71 89 67 34 k ' S '<? 37 11 39
12 32 12 73 71 12 9 15 83 10 59
13 36 37 61 69 ' 77 17 29 88 ? 81 96
14 81 79 96 63 10 30 18 91 37 14
15 58 97 : 86 73 55 34 6 29 • 86 81
16 42 33 5 ,19 95 34 97 35 2 41
17 30 24 21 51 3 47 29 36 .’••• 59 50
18 16 19 96 16 58 53 32 2 3 19
19 84 57 33 60 69 69 86 89 28 ... 6




YOU ARE INVITED TO PARTICIPATE 
IN A STUDY INTERVIEW
As a participant in this study, you would be asked to 
complete a Mini, Mental Status Exam. 
followed by a short- interview. . .
■Participation in this study is 
voluntary and confidential, ‘
In appreciation of your time you will 
receive $15' cash-.
' Your., participation would involve coming to
■ The MHA drop-in center in Santa Ana' 
On January 27th for approximately one hour.'
For more information about this study, or to ■■ 
Volunteer for this study, please, . contact:
Nicole Nanchy or -Michelle Green,. . • ’ ■
Social Work Graduate Students.-. .'
‘ ‘ ' or your PSC at (714) 668-8498.
This study has been approved by. the Institutional Review 
Board for California State University San Bernardino
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APPENDIX D
MINI MENTAL STATUS EXAM
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SCORE (1 point per right answer)
ORIENTATION
5 Wbat is the? (year) (season) (date) (day) (month)
5 Where are we? (state) (county) (city) ( hospital) ( (floor)
REGISTRATION
3 Name 3 common objects (e.g. apple, table, penny). Take 1 second to pronounce 
each word. The ask the patient to repeat all 3 words. Give one point for each correct 
answer.
ATTENTION AND CALCULATION
5 Ask the patient to spell “WORLD” backwards. The score is the number of letters in 
correct order (D_L_R_O_W_).
RECALL
3 Ask the patient for the three objects repeated above. Give 1 point for each correct 
answer. (Note: Recall cannot be tested if all 3 objects were not remembered during 
registration.)
LAUNGAGE
2 Show the patient a “pencil” and a “watch” and ask him/her to name them.
1 Ask patient to repeat the following: [ No its, ands or buts]
3 Ask patient to follow a 3-stage command:
[ take a paper in your right hand, fold it in hal£ and put it on the floorj
Ask the patient to read and obey the following:
• Close your eyes.
• Write a sentence









Severe: MMSE < 9
Based on this assessment, is this individual cognitively capable to participate in this 
study? (circle one) YES / NO
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Mini Mental Status Exam (MMSE)
ID#______________________________Date:______________________________
This paper is to be used for MMSE participants to respond to written questions. Please attach this sheet 





Informed Consent for Participation in the Interview
Title of Research: An Exploratory Study of Barriers to Psychotropic Adherence 
from the Client’s Perspective.
Name of Researchers: Nicole Nanchy and Michelle Green, Social Work 
Graduate Students
You are invited to participate in a research study exploring barriers to 
treatment adherence. First, you will be asked to participate in a Mini Mental 
Status Exam. Next, you may be asked to participate in an interview lasting 
approximately one hour. Participation is this study is voluntary and 
confidential. You are free to withdraw from this study or decline answering any 
questions at anytime without being asked why you have made this decision.
There are no foreseen risks beyond those of everyday life. The benefit you 
may receive for your participation in this study is the opportunity to share your 
experiences with mental health services, specifically, your experience taking 
psychotropic medication. Your involvement in this study will help identify 
barriers to treatment, which may lead to better mental health practices. You 
will receive a Visa gift certificate for $15 in return for your time and effort.
This study has been approved by the Institutional Review Board for California 
State University, San Bernardino.
If you have any questions or concerns please contact research advisor, 
Herbert Shon, Ph.D., L.C.S.W. at (909) 537-5532.
Please check the box below to indicate that you have read this informed 
consent and choose to participate in this interview. By checking this box you 
are also verifying that you are 18-years of age or older.






Title of Research: An Exploratory Study of Barriers to Psychotropic Adherence 
from the Client’s Perspective.
Name of Researchers: Nicole Nanchy and Michelle Green, Social Work 
Graduate Students
We would like to take this time to thank you for your participation in this study. 
You have participated in a research study that explored people’s opinions and 
beliefs about psychiatric medications. You were asked to participate in a Mini 
Mental Status Exam and a one-to-one interview. Participation is this study was 
anonymous and confidential.
We ask all participants to avoid discussing the nature of this study with other 
participants as it may influence their responses. A copy of the study results will 
be provided and available to you through the Mental Health Association of 
Orange County, AB2034 Program by September 15, 2006.
If you have any concerns about having participated in this research study, 






empowerment In social work practice, the process of helping individuals, 
families, groups, and communities increase their personal, 
socioeconomic, and political strength, and develop influence toward 
improving their circumstances (Barker, 2003).
evidenced-based practice (EBP) The use of the best available scientific 
knowledge derived from randomized controlled outcome studies, and 
meta-analysis of existing outcome studies, as one basis for guiding 
professional interventions and effective therapies, combined with 
professional ethical standards, clinical judgment, and practice wisdom 
(Barker, 2003).
macro practice Social work practice aimed at bringing about improvements 
and changes in the general society. Such activities include some types 
of political action, community organizations, public education 
campaigning, and the administration of broad-based Social services 
agencies or public welfare departments (Barker, 2003).
medical model An approach to helping people that is patterned after the 
orientation used by many physicians. This includes looking at the 
clients as an individual with an illness to be treated, giving relatively 
less attention to factors in the clients environment, diagnosing the 
condition with fairly specific labels, and treating the problems through 
regular clinical appointments (Barker, 2003).
mental status exam mini A systematic evaluation of a patients level of 
psychosocial, intellectual, and emotional functioning (Barker, 2003).
micro practice The term used by social workers to identify professional 
activities that are designed to help solve the problems faced primarily 
by individuals, families, and small groups. Usually micro practice 
focuses on direct interventions on a case-by-case basis or in a clinical 
setting (Barker, 2003). \
pharmacotherapy The administration of medications to help maximize the 
physical or mental health potential of a patient. This includes educating 
the patient about the need for the drug and its proper use, monitoring, 
and taking efforts to modify the prescription as needed. Counseling 
support are also important (Barker, 2003).
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DEFINITION OF TERMS
psychoeducation The process of teaching clients with a mental illness and 
\ their family members about the nature Of the illness, including its 
etiology, progression, consequences, prognosis, treatment, and 
alternatives (Baker, 2003).
psychopharmacology The study and use of drugs to bring about changes in 
behavior and personality (Barker, 2003).
psychosis Psychotic episode A serious and frequently incapacitating mental 
disorder that may be of organic or psychological origin. These disorders 
are characterized by some or all of the following symptoms: impaired 
thinking and reasoning ability, perceptual distortions, inappropriate 
emotional responses, inappropriate affect, regressive behavior, reduced 
impulse control, impaired reality testing, ideas of reference, 
hallucinations, and delusions,(Barker, 2003).
psychotropic Drugs used by psychiatrists to help their patients achieve 
psychological or emotional changes (Barker, 2003). Classifications:
1. Antipsychotics (such as; Thorazine, Haldol, Prolixin).
2. Antidepressents (such as; Prozac, Elavil, Norpramin).
3. Antimanics (Lithium carbonate-that is, Eskalith, Lithane, or 
Lithonate).
4. Antianxiety agents (such as; Valium, Ativan & various barbiturates). 
(Barker, 2003).
rational emotive therapy A psychotherapeutic method based on the cognitive 
theory of psychologist Albert Ellis, in which the client is encouraged to 
make distinctions between what is objective fact in the environment and 
the inaccurate, negative, and self-Jimiting interpretations made of one’s 
own. behavior and life (Barker, 2003).
reality theory Psychosocial and behavioral intervention, developed by William 
Glasser, that focuses on the clients behavior rather than the past. 
Therapists encourage working out alternative solutions to problems. 
They do not accept client excuses, rarely ask “why,” and place little 







Frequency Percent Valid Percent
Cumulative 
Percent .
Valid Male 6 37.5 37.5 37.5
Female 10 62.5 62.5 100.0
Total .16 100.0 100.0
Age
Table 2
Frequency Percent Valid Percent
Cumulative 
Percent
Valid 24.00 1 6.3 6.3 6.3
29.00 1 6.3; 6.3 12.5
31.00 2 12.5 12:5 25.0
32.00 . 1 6.3 6.3 31.3
36.00 1 6.3 6.3 37.5
44.00 2 12.5 12.5 50.0
45.00 1 6.3 ‘ 6.3 56.3
46.00 2 12.5 12.5 68.8
47.00 1 6.3 6.3 75.0
50.00 1 6.3 6.3 81.3
51.00 1 6.3 6.3 87.5
59.00 1 6.3 6.3 93.8
61.00 1 6.3’ 6.3 . 100.0
Total 16 100.0 100.0
Race
Table 3
Frequency Percent Valid Percent
Cumulative 
Percent
Valid White Caucasian 8 50.0 50.0 50.0
Black or African American 3 18.8 18.8 68.8
Other 3 18.8 18.8 87.5
Refused to answer
question. 2 12.5 12.5 100.0




Frequency Percent Valid Percent
Cumulative 
Percent
Valid Single/never married 8 50.0 50.0 50.0
Separated 1 6.3 6.3 56.3
Divorced 6 37.5 37.5 93.8
Widowed 1 6.3 6.3 100.0
Total 16 100.0 100.0
Table 5
Employment Status
Frequency Percent Valid Percent
Cumulative 
Percent
Valid unemployed 15 93.8 93.8 93.8
Part-time 1' 6.3 6.3 100.0
Total 16 100.0 ' 100.0
Education
Table 6
Frequency Percent Valid Percent
Cumulative 
Percent
Valid 8th grade of less 2 .. 12.5 12.5 12.5
Some High School 3 18.8 18.8 31.3
H.S. Graduate or GED 5 31.3 31.3 62.5
Some College or 2yr. 
Degree 6 37.5 37.5 100.0




Frequency Percent Valid Percent
Cumulative 
Percent
Valid Hospitalized for Psych Tx 2 12.5 12.5 12.5
Incarcerated 2 12.5 12.5 25.0
Substance Detox ' 1 6.3 6.3 31.3
None. 8 50.0 50.0 81.3
Psych hospitalization 
and incarceration. 2 12.5 12.5 . 93.8
Incarceration and 
substance detox. 1. 6.3 6.3 100.0




Frequency Percent Valid Percent
Cumulative 
Percent
Valid Less than 2 yrs. 1 6.3 6.3 6.3
2- 5 years 4 25.0 25.0 31.3
5-7 years 2 12.5 . 12.5 43.8
7-10 years 2 12.5 12.5 56.3
More than 10 years 7 43.8 43.8 100.0
Total 16 100.-0 100.0
Housing
Table 9
Frequency Percent Valid Percent
Cumulative 
Percent
Valid Homeless 3 18.8 18.8 18.8
Independent 9 56.3 56.3 75.0
with Family 1 6.3 6.3 81.3
Sober Living Facility .2 ■ 12.5 12.5 93.8
Other 1 6.3 6.3 100.0




Frequency Percent Valid Percent
Cumulative 
Percent
Valid Schizophrenia 5 31.3 31.3 31.3
Schizoaffective Disorder 2 12.5 12.5 43.8
Bipolar Disorder 5 31.3 31.3 75.0
Major Depressive 
Disorder 1 6.3 6.3 81.3
Schizoaffective, Bipolar, 
Schizophrenia 1 6.3 6.3 87.5
Schizophrenia and Major 
Depressive Disorder. 1 6.3 6.3 93.8
Bipolar, Schizoaffective 1 6.3 6.3 100.0
Total 16 100.0 100.0
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